Humacyte Inc
$ 1.39
-4.14%
02 Jun - close price
- Market Cap 306,386,000 USD
- Current Price $ 1.39
- High / Low $ 1.48 / 1.36
- Stock P/E N/A
- Book Value 0.02
- EPS -0.63
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.52 %
- ROE -4.09 %
- 52 Week High 2.93
- 52 Week Low 0.55
About
Humacyte Inc (HUMA) is an innovative biotechnology firm at the forefront of vascular and regenerative medicine, specializing in the development of human acellular vessels (HAVs) aimed at addressing critical clinical demands in vascular reconstruction and chronic disease management. By offering off-the-shelf solutions, Humacyte enhances patient outcomes while aiming to reduce overall healthcare expenditures. Leveraging its cutting-edge technology platform, the company is well-positioned to lead advancements in transplantation and tissue engineering, establishing itself as a key player in the rapidly evolving medical therapies sector.
Analyst Target Price
$1.90
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-27 | 2025-11-12 | 2025-08-11 | 2025-05-13 | 2025-03-28 | 2024-11-08 | 2024-08-13 | 2024-05-10 | 2024-03-22 | 2023-11-09 | 2023-08-14 |
| Reported EPS | -0.09 | -0.188 | -0.11 | -0.24 | -0.0804 | -0.2091 | -0.33 | -0.48 | -0.29 | -0.24 | -0.25 | -0.22 |
| Estimated EPS | -0.122 | -0.1284 | -0.16 | -0.16 | -0.22 | -0.255 | -0.25 | -0.24 | -0.22 | -0.24 | -0.25 | -0.22 |
| Surprise | 0.032 | -0.0596 | 0.05 | -0.08 | 0.1396 | 0.0459 | -0.08 | -0.24 | -0.07 | 0 | 0 | 0 |
| Surprise Percentage | 26.2295% | -46.4174% | 31.25% | -50% | 63.4545% | 18% | -32% | -100% | -31.8182% | 0% | 0% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HUMA
2026-06-01 21:39:23
Benchmark has increased its price target for Humacyte Inc. (NASDAQ:HUMA) to $2.00 from $1.00, maintaining a Speculative Buy rating, due to promising prospects for the company's dialysis arteriovascular access indication, which is expected to launch in 2027. Despite challenges in gaining sales traction for its Symvess product in vascular trauma, new marketing efforts and a VA contract could boost U.S. sales, and a significant order from Saudi Arabia is anticipated. The company is also set to present follow-up data from its V012 clinical trial in June, with the product potentially becoming commercially available in 2027 after FDA review.
2026-06-01 14:39:23
Humacyte reported its Q1 2025 earnings, highlighting initial commercial shipments of Symvess for extremity vascular trauma and $517,000 in revenue. The company detailed ongoing progress in securing hospital approvals, advancing its pipeline with Phase 3 trials for dialysis access and plans for an IND filing for coronary artery bypass grafting, and implementing cost-saving measures including a workforce reduction. Despite noting a "headwind" from a New York Times article affecting some hospital purchase reviews, management remains confident in Symvess's market penetration and the company's financial runway.
2026-05-31 00:39:23
Humacyte recently announced new research on its acellular tissue engineered vessel (ATEV) program, highlighting long-term structural integrity, self-repair capabilities, and reduced infection susceptibility compared to ePTFE grafts. The company also confirmed that top-line Phase 3 V012 dialysis access results are expected on June 11, 2026. This data, coupled with existing trials and an approved vascular trauma indication, underscores the potential of Humacyte's platform to address chronic vascular access issues, but investors should also consider ongoing Nasdaq listing risks.
2026-05-30 21:11:52
Humacyte's stock (HUMA) rose 23.8% following new data on its acellular tissue engineered vessel (ATEV) program, which demonstrated long-term structural integrity and self-repair capabilities, along with reduced infection susceptibility. The company also confirmed that top-line Phase 3 V012 dialysis access results are expected on June 11, 2026. This positive development reinforces Humacyte's potential to address chronic vascular access challenges and could significantly influence its investment narrative, especially with an approved vascular trauma indication already in place.
2026-05-29 17:09:33
Humacyte, Inc. (NASDAQ:HUMA) has appointed Todd E. Rasmussen, M.D., as its new Chief Surgical Officer. Dr. Rasmussen, a veteran of the U.S. Air Force and a professor at Mayo Clinic, will provide scientific support and technical insights for Humacyte's products, including its FDA-approved acellular tissue engineered vessel. The company is also conducting late-stage clinical trials for other vascular applications and analysts project significant revenue growth for fiscal 2026.
2026-05-26 22:39:42
H.C. Wainwright has reiterated its Buy rating for Humacyte (HUMA.US), maintaining a target price of $3. This indicates the firm's continued positive outlook on the company's stock performance and potential.
